Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma

被引：9
|
作者：
Mollica, Veronica [1 ]
Di Nunno, Vincenzo [1 ]
Massari, Francesco [1 ]
机构：
[1] St Orsola Marcello Malpighi Hosp, Div Oncol, Via Albertoni 15, I-40138 Bologna, Italy
来源：
CHINESE CLINICAL ONCOLOGY | 2019年 / 8卷
关键词：
D O I：
10.21037/cco.2019.04.05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：4
相关论文
共 50 条
  • [31] KEYNOTE-426Axitinib plus Pembrolizumab vs. Sunitinib in der Erstlinientherapie des metastasierten NierenzellkarzinomsKEYNOTE-426Axitinib plus pembrolizumab vs sunitinib in the first-line treatment of metastatic renal cell carcinoma
    J. Bedke
    V. Stühler
    Der Urologe, 2020, 59 (7): : 841 - 842
  • [32] Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis
    Yamashita, Shimpei
    Kawabata, Hiroki
    Iwahashi, Yuya
    Muraoka, Satoshi
    Wakamiya, Takahito
    Kojima, Fumiyoshi
    Kohjimoto, Yasuo
    Murata, Shin-ichi
    Hara, Isao
    IJU CASE REPORTS, 2025,
  • [33] Axitinib for the Management of Metastatic Renal Cell Carcinoma
    Escudier, Bernard
    Gore, Martin
    DRUGS IN R&D, 2011, 11 (02) : 113 - 126
  • [34] Axitinib for the management of metastatic renal cell carcinoma
    Escudier B.
    Gore M.
    Drugs in R & D, 2011, 11 (2) : 113 - 126
  • [35] The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
    Wang, Zhixin
    Chen, Jiaqi
    Li, Qianyu
    Li, Na
    Yu, Jing
    Liu, Feng
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [36] Real-world outcomes in patients with metastatic clear cell renal cell carcinoma receiving front-line axitinib plus pembrolizumab versus ipilimumab plus nivolumab.
    Zarrabi, Kevin
    Handorf, Elizabeth A.
    Miron, Benjamin
    Zibelman, Matthew R.
    Anari, Fern
    Ghatalia, Pooja
    Plimack, Elizabeth R.
    Geynisman, Daniel M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
    McGregor, Bradley
    Geynisman, Daniel M.
    Burotto, Mauricio
    Suarez, Cristina
    Bourlon, Maria T.
    Barata, Pedro C.
    Gulati, Shuchi
    Huo, Stephen
    Ejzykowicz, Flavia
    Blum, Steven I.
    Del Tejo, Viviana
    Hamilton, Melissa
    May, Jessica R.
    Du, Ella X.
    Wu, Aozhou
    Kral, Pavol
    Ivanescu, Cristina
    Chin, Andi
    Betts, Keith A.
    Lee, Chung-Han
    Choueiri, Toni K.
    Cella, David
    Porta, Camillo
    EUROPEAN UROLOGY ONCOLOGY, 2023, 6 (03): : 339 - 348
  • [38] A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma
    Shay, Rebecca
    Nicklawsky, Andrew
    Gao, Dexiang
    Lam, Elaine T.
    CLINICAL GENITOURINARY CANCER, 2021, 19 (04) : 370 - +
  • [39] Pembrolizumab plus axitinib (pembro plus axi) vs sunitinib in metastatic renal cell carcinoma (mRCC) outcomes of the KEYNOTE-426 study in patients from eastern Asia
    Kondoh, C. N.
    Bae, W. K.
    Tamada, S.
    Matsubara, N.
    Lee, H. J.
    Mizuno, R.
    Ani, S.
    Kimura, G.
    Tomita, Y.
    Chang, C-H.
    Chang, J. W-C.
    Lin, J.
    Perini, R.
    Molife, L. R.
    Powles, T. B.
    Rini, B.
    Chung, H-J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1319 - S1319
  • [40] Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma
    Hideaki Miyake
    Ken-ichi Harada
    Seiichiro Ozono
    Masato Fujisawa
    Medical Oncology, 2016, 33
12345